기본 통계
| LEI | 5299004HFYSAZM2ALW85 |
| CIK | 1133416 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Galectin Therapeutics Inc Warrants
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2026 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2026 |
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update Exhibit 99.1 Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026. “We continue to make meaning |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. |
|
| April 8, 2026 |
April 8, 2026 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| April 6, 2026 |
April 6, 2026 Joel Lewis Chief Executive Officer and President Galectin Therapeutics Inc. |
|
| March 31, 2026 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Galectin Therapeutics, Inc. |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2026 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 31, 2026 |
Exhibit 21.1 SUBSIDIARIES OF REGISTRANT The following is a list of the Corporation’s subsidiaries as of December 31, 2025. The Corporation owns, directly or indirectly, 100% of the voting securities of each subsidiary, unless noted otherwise. NAME STATE OR JURISDICTION OF ORGANIZATION Galectin Therapeutics Security Corp. Delaware Galectin Sciences LLC Georgia |
|
| March 31, 2026 |
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update Exhibit 99.1 Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025. Joel Lewis, Chief Executive Officer and P |
|
| March 31, 2026 |
TABLE OF CONTENTS Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 2834 04-3562325 (State or other jurisdiction of incorporation or organization) (Primary SIC Number) |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevad |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2026 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 17, 2026 |
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. Exhibit 99.1 Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced it has appointed Henry Brem, M.D., as an independent director to its Board |
|
| January 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2026 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2026 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 19, 2025 |
FORM OF CONVERTIBLE PROMISSORY NOTE CONVERTIBLE PROMISSORY NOTE Exhibit 10.2 EXHIBIT A FORM OF CONVERTIBLE PROMISSORY NOTE CONVERTIBLE PROMISSORY NOTE $ Atlanta, Georgia Dated as of FOR VALUE RECEIVED, the undersigned, GALECTIN THERAPEUTICS, INC., a Nevada corporation (the “Company”), hereby unconditionally promises to pay to the order of Richard E. Uihlein, an individual resident of the State of Illinois (“Lender”), whose office address is 12575 Uline Drive, |
|
| December 19, 2025 |
Exhibit 99.1 Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 NORCROSS, Ga., December 19, 2025 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients wi |
|
| December 19, 2025 |
DECEMBER 2025 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT Exhibit 10.1 DECEMBER 2025 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT December 19, 2025 GALECTIN THERAPEUTICS, INC. 4960 Peachtree Industrial Blvd., Suite 240 Norcross, Georgia 30071 Directors and Officers of Galectin Therapeutics, Inc.: This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”), that certain Supplemental L |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2025 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 19, 2025 |
FORM OF COMMON STOCK PURCHASE WARRANT Exhibit 4.1 EXHIBIT B FORM OF COMMON STOCK PURCHASE WARRANT NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY |
|
| December 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 3, 2025 |
Exhibit 99.1 Thanks Kevin, Since I became President and CEO of Galectin Therapeutics, I can honestly say that I have never been as excited as I am today, nor have I had the luxury of sharing such an extensive amount of meaningful information. As I am writing this to you, frankly, the only appropriate word I can think of is, wow! Around a year ago, I think it’s safe to say, we had many doubters. An |
|
| November 14, 2025 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update NORCROSS, Ga., November 14, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended Sep |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period fromto Commission File No. 001-31791 GALECTIN THERAPEUTICS IN |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 10, 2025 |
Exhibit 99.1 Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting • New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kg • Using established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg |
|
| November 10, 2025 |
Exhibit 99.2 Galectin TherapeuticsCorporate OverviewNovember 2025 Forward-Looking Statements This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and o |
|
| October 22, 2025 |
$118$/ 5(3257 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 22, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| October 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| September 12, 2025 |
144 0001725595 XXXXXXXX LIVE 0001133416 GALECTIN THERAPEUTICS INC 001-31791 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186 LEWIS JOEL Officer Common Stock Stifel Nicolaus & Company Inc 501 N Broadway St. |
|
| September 12, 2025 |
144 0001266773 XXXXXXXX LIVE 0001133416 GALECTIN THERAPEUTICS INC 001-31791 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186 CALLICUTT JACK W Officer Common Stock Stifel Nicolaus & Company Inc 501 N Broadway St. |
|
| September 8, 2025 |
Exhibit 99.1 Galectin TherapeuticsCorporate OverviewSeptember 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on |
|
| September 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 14, 2025 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the quarter ended June 30, 2025 and Provides Business Update NORCROSS, Ga., August 14, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and six months ended June 30, 202 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. N |
|
| July 9, 2025 |
Exhibit 99.1 Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through June 2026 NORCROSS, Ga., July 9, 2025 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal h |
|
| July 9, 2025 |
FORM OF CONVERTIBLE PROMISSORY NOTE CONVERTIBLE PROMISSORY NOTE Exhibit 10.2 FORM OF CONVERTIBLE PROMISSORY NOTE CONVERTIBLE PROMISSORY NOTE $ Atlanta, Georgia Dated as of , 2025 FOR VALUE RECEIVED, the undersigned, GALECTIN THERAPEUTICS, INC., a Nevada corporation (the “Company”), hereby unconditionally promises to pay to the order of Richard E. Uihlein, an individual resident of the State of Illinois (“Lender”), whose office address is 12575 Uline Drive, Ple |
|
| July 9, 2025 |
JULY 2025 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT Exhibit 10.1 JULY 2025 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT July 8, 2025 GALECTIN THERAPEUTICS, INC. 4960 Peachtree Industrial Blvd., Suite 240 Norcross, Georgia 30071 Directors and Officers of Galectin Therapeutics, Inc.: This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”), that certain Supplemental Line of Cr |
|
| July 9, 2025 |
FORM OF COMMON STOCK PURCHASE WARRANT Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SH |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 8, 2025 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 16, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2025 |
Exhibit 99.1 Belapectin for MASH Cirrhosis and Portal Hypertension June 2025 Khurram Today’s Agenda 01 02 03 04 05 06 Moderator Michael Cozart, LifeSci Consulting Galectin Company Introduction Joel Lewis (CEO & President) Belapectin as Galectin-3 Inhibitor for MASH cirrhosis & Portal Hypertension Khurram Jamil, M.D. (CMO) Unmet Need & Patient Landscape Naga Chalasani, M.D. Clinical Results – NAVIG |
|
| May 15, 2025 |
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update Exhibit 99.1 Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer an |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2025 |
Exhibit 99.1 Galectin TherapeuticsCorporate OverviewMay 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our c |
|
| May 12, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 12, 2025 |
Exhibit 99.2 Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress • Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). • Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). • Significantly fewer |
|
| March 31, 2025 |
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update Exhibit 99.1 Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2024. Joel Lewis, Chief Executive Officer and P |
|
| March 31, 2025 |
Subsidiaries of Galectin Therapeutics Inc. Exhibit 21.1 SUBSIDIARIES OF REGISTRANT The following is a list of the Corporation’s subsidiaries as of December 31, 2024. The Corporation owns, directly or indirectly, 100% of the voting securities of each subsidiary, unless noted otherwise. NAME STATE OR JURISDICTION OF ORGANIZATION Galectin Therapeutics Security Corp. Delaware Galectin Sciences LLC Georgia |
|
| March 31, 2025 |
Exhibit 19 Galectin Therapeutics Inc. Amended and Restated Insider Trading Policy Adopted by the Board of Directors on December 1, 2022 Purpose This Insider Trading Policy (the “Policy”), which amends and restates the prior Insider Trading Policy adopted October 4, 2011, provides guidelines with respect to transactions in the securities of Galectin Therapeutics Inc. (the “Company”) and the handlin |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevad |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 31, 2025 |
Exhibit 10.21 MARCH 2025 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT March 31, 2025 GALECTIN THERAPEUTICS, INC. 4960 Peachtree Industrial Blvd., Suite 240 Norcross, Georgia 30071 Directors and Officers of Galectin Therapeutics, Inc.: This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”), that certain Supplemental Line o |
|
| March 5, 2025 |
Exhibit 99.1 Galectin TherapeuticsCorporate OverviewFebruary 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 18, 2025 |
Exhibit 99.1 Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial • Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs placebo in per-protocol patients (completers) enrolled in the U.S. • New estimates indicat |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 18, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 23, 2025 |
2024 ANNUAL MEETING OF STOCKHOLDERS Thursday, January 23, 2025 11:00 a.m. (Eastern Time, US) Exhibit 99.1 Thank you, Kevin, and thank you to everyone for joining the call this morning. Please note that certain statements made today are forward looking in nature. Please see the forward-looking statements disclaimer attached to the Agenda for the Annual Meeting at the end of the transcript of this presentation. As most of you are aware 2024 was a monumental year for Galectin Therapeutics, a |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 13, 2025 |
Exhibit 99.1 Galectin TherapeuticsCorporate OverviewJanuary 2025 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on o |
|
| December 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2024 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 20, 2024 |
Exhibit 99.1 Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH • In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo • While there was a favorable tr |
|
| December 3, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| December 3, 2024 |
$118$/ 5(3257 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2024 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2024 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS I |
|
| November 14, 2024 |
Exhibit 99.1 Galectin TherapeuticsCorporate OverviewNovember 2024 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on |
|
| November 14, 2024 |
NOVEMBER 2024 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT Exhibit 10.1 NOVEMBER 2024 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT November 14, 2024 GALECTIN THERAPEUTICS, INC. 4960 Peachtree Industrial Blvd., Suite 240 Norcross, Georgia 30071 Directors and Officers of Galectin Therapeutics, Inc.: This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”) and that certain Supplementa |
|
| November 14, 2024 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update • NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., November 14, 2024 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and pro |
|
| September 9, 2024 |
Exhibit 99.1 Galectin TherapeuticsCorporate OverviewAugust 2024 2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on ou |
|
| September 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2024 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. N |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2024 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 13, 2024 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update • NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., August 13, 2024 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p |
|
| August 1, 2024 |
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer Exhibit 99.1 Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer NORCROSS, Ga., August 1, 2024 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer eff |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2024 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 1, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made August 1, 2024, by and between Galectin Therapeutics Inc., a Nevada corporation (the “Company”), and Khurram Jamil, MD, an individual residing in the State of Pennsylvania (“Executive”). W I T N E S S E T H: WHEREAS, Executive is currently employed by the Company as its Vice President Clinical Development Medica |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2024 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. |
|
| May 15, 2024 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update • Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) • NAVIGATE trial remains on track f |
|
| March 29, 2024 |
Form of Common Stock Purchase Warrant Exhibit 4.12 NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON TH |
|
| March 29, 2024 |
Form of Stock Option Award Agreement under Galectin Therapeutics 2019 Omnibus Equity Incentive Plan Exhibit 10.2 GALECTIN THERAPEUTICS INC. STOCK OPTION AGREEMENT FOR Agreement 1. Grant of Option. Galectin Therapeutics Inc., a Nevada corporation (the “Company”) hereby grants, as of (“Date of Grant”), to (the “Optionee”) an option (the “Option”) to purchase up to shares of the Company’s common stock, $ par value per share (the “Shares”), at an exercise price per share equal to $1.72 (the “Exercis |
|
| March 29, 2024 |
Executive Compensation Clawback Policy Exhibit 97 GALECTIN THERAPEUTICS INC. CLAWBACK POLICY 1. Introduction The Board of Directors (the “Board”) of Galectin Therapeutics Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and foster a culture of business ethics, integrity and accountability, and that, among other purposes, reinforces the Company’s incentive compensation philosop |
|
| March 29, 2024 |
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update Exhibit 99.1 Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. Joel Lewis, Chief Executive Officer and P |
|
| March 29, 2024 |
Warrant Extension Agreement between the Company and 10X Fund L.P. Exhibit 4.11 September 22, 2023 10X Fund L.P. 545 Dutch Valley Road, N.E., Suite A Atlanta, Georgia 30324 Attn: Jim Czirr Re: Amendment and Restatement of 5,732,253 Common Stock Purchase Warrants held by 10X Fund L.P. or 10X Capital Management LLC Dear Jim: This letter agreement (this “Letter Agreement”) confirms the agreement between Galectin Therapeutics, Inc. (the “Company”) and 10X Fund L.P. a |
|
| March 29, 2024 |
Subsidiaries of Galectin Therapeutics Inc. Exhibit 21.1 SUBSIDIARIES OF REGISTRANT The following is a list of the Corporation’s subsidiaries as of December 31, 2023. The Corporation owns, directly or indirectly, 100% of the voting securities of each subsidiary, unless noted otherwise. NAME STATE OR JURISDICTION OF ORGANIZATION Galectin Therapeutics Security Corp. Delaware Galectin Sciences LLC Georgia |
|
| March 29, 2024 |
Exhibit 10.3 Restricted Stock Unit Agreement under the Galectin Therapeutics Inc. 2019 Omnibus Equity Compensation Plan Pursuant to the terms of the Galectin Therapeutics Inc. 2019 Omnibus Equity Compensation Plan (the “Plan”), Galectin Therapeutics Inc., a Nevada corporation (together with all successors thereto, the “Company”), hereby enters into this Restricted Stock Unit Agreement with the und |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2024 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 29, 2024 |
Exhibit 10.19 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENT March 29, 2024 GALECTIN THERAPEUTICS, INC. 4960 Peachtree Industrial Blvd., Suite 240 Norcross, Georgia 30071 Directors and Officers of Galectin Therapeutics, Inc.: This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”) between Galectin Therapeutics, Inc., a Nevad |
|
| March 29, 2024 |
Form of Convertible Promissory Note issued to Richard E. Uihlein Exhibit 10.20 EXHIBIT A FORM OF CONVERTIBLE PROMISSORY NOTE CONVERTIBLE PROMISSORY NOTE $ Atlanta, Georgia Dated as of , 2024 FOR VALUE RECEIVED, the undersigned, GALECTIN THERAPEUTICS, INC., a Nevada corporation (the “Company”), hereby unconditionally promises to pay to the order of Richard E. Uihlein, an individual resident of the State of Illinois (“Lender”), whose office address is 12575 Uline |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevad |
|
| December 11, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2023 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 7, 2023 |
Exhibit 99.1 Thanks Kevin and thank you to everyone joining us today. Please note that certain statements made today are forward looking in nature. Please see the forward-looking statements disclaimer attached to the Agenda for the Annual Meeting at the end of the transcript of this presentation. As I thought about 2023 from the perspective of Galectin Therapeutics, the Board and our shareholders, |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2023 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 1, 2023 |
Form of Amended and Restated Class B-3 Common Stock Purchase Warrant EX-3 4 exf.htm Exhibit F NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSU |
|
| December 1, 2023 |
Form of Amended and Restated Class B Common Stock Purchase Warrant EX-2 3 exe.htm Exhibit E NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”) OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHAR |
|
| December 1, 2023 |
Settlement Agreement dated December 17, 2018 EX-1 2 exd.htm Exhibit D SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release (this “Agreement”) is entered into between Galectin Therapeutics, Inc., a Nevada corporation (the “Company”) and 10X Fund, LP, a Delaware Limited Partnership (“10X Fund” as of December 17, 2018 (the “Effective Date”): R E C I T A L S Recital A. The Company is a clinical stage biopharmaceutical company e |
|
| December 1, 2023 |
Form of Amended and Restated Lock-Up Common Stock Purchase Warrant EX-4 5 exg.htm Exhibit G NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSU |
|
| December 1, 2023 |
ESCC / Evans & Sutherland Computer Corp. / 10x Fund, L.p. Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 13)* GALECTIN THERAPEUTICS, INC. (Name of Issuer) Common Stock $0.001 par value per share (Title of Class of Securities) 299096 107 (CUSIP Number) James C. Czirr 10X Capital Management, LLC 545 Dutch Valley Road, N.E., Suite A Atl |
|
| November 13, 2023 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update NORCROSS, Georgia, November 13, 2023 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS I |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 13, 2023 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update NORCROSS, Georgia, November 13, 2023 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September |
|
| October 6, 2023 |
TABLE OF CONTENTS United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| October 6, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S |
|
| August 14, 2023 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update NORCROSS, Georgia, August 14, 2023 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2023. T |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. N |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 GALECTIN THERAPEUTICS INC (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 15, 2023 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update NORCROSS, Georgia, May 15, 2023 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2023. Th |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. |
|
| April 20, 2023 |
April 20, 2023 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| April 19, 2023 |
United States securities and exchange commission logo April 19, 2023 Joel Lewis Chief Executive Officer and President GALECTIN THERAPEUTICS INC 4960 Peachtree Industrial Blvd. |
|
| April 14, 2023 |
TABLE OF CONTENTS Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 2834 04-3562325 (State or other jurisdiction of incorporation or organization) (Primary SIC Number) (I.R.S. Employer Identificatio |
|
| April 14, 2023 |
EX-FILING FEES 4 ny20008653x1ex107.htm FILING FEES TABLE Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Galectin Therapeutics, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum |
|
| March 30, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 30, 2023 |
Exhibit 3.7 FRANCISCO V. AGUILAR Secretary of State GABRIEL DI CHIARA Chief Deputy STATE OF NEVADA OFFICE OF THE SECRETARY OF STATE Commercial Recordings Division 202 N. Carson Street Carson City, NV 89701 Telephone (775) 684-5708 Fax (775) 684-7138 North Las Vegas City Hall 2250 Las Vegas Blvd North, Suite 400 North Las Vegas, NV 89030 Telephone (702) 486-2880 Fax (702) 486-2888 Business Entity - |
|
| March 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) GALECTIN THERAPEUTICS INC. |
|
| March 30, 2023 |
Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update Exhibit 99.1 Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2022. These results are included in the Company |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevad |
|
| March 30, 2023 |
Subsidiaries of Galectin Therapeutics Inc. Exhibit 21.1 SUBSIDIARIES OF REGISTRANT The following is a list of the Corporation’s subsidiaries as of December 31, 2022. The Corporation owns, directly or indirectly, 100% of the voting securities of each subsidiary, unless noted otherwise. NAME STATE OR JURISDICTION OF ORGANIZATION Galectin Therapeutics Security Corp. Delaware Galectin Sciences LLC Georgia |
|
| March 30, 2023 |
Registration Statement No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 04-3562325 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 4960 Peachtree Industrial Blvd., Sui |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 2, 2023 |
Exhibit 99.1 Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis NORCROSS, Ga., March 2, 2023 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 202 |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2023 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 5, 2023 |
Exhibit 99.1 Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis NORCROSS, Ga., January 5, 2023 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 1, 2022 |
Exhibit 99.1 Thanks Kevin, and thank you to everyone joining us today. Out of an abundance of caution, management and the Board made the decision to hold our meeting virtually due to uncertainty surrounding Covid-19 at the time of planning the meeting. Please note that certain statements made today are forward looking in nature. Please see the forward-looking statements disclaimer attached to the |
|
| November 14, 2022 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update NORCROSS, Ga., November 14, 2022 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS I |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 17, 2022 |
TABLE OF CONTENTS United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| October 17, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 12, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 12, 2022 |
Exhibit 99.1 Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer NORCROSS, Ga., October 12, 2022 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced that its Investigational New Drug (IND) application for belapectin in combination with a checkpoin |
|
| October 6, 2022 |
TABLE OF CONTENTS United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.????) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commissi |
|
| October 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 6, 2022 |
Exhibit 99.1 Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis NORCROSS, Ga., October 6, 2022 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that tar |
|
| August 15, 2022 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update NORCROSS, Ga., August 15, 2022 (GLOBE NEWSWIRE) ? Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022. These |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. N |
|
| July 26, 2022 |
Exhibit 4.1 NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF SUCH WARRANTS, NOR ANY INTEREST IN OR RIGHTS UNDER SAME, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE LAWS OF ANY STATE, AND NEITHER THIS WARRANT CERTIFICATE NOR THE WARRANTS REPRESENTED HEREBY NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON THE |
|
| July 26, 2022 |
Exhibit 10.2 FORM OF CONVERTIBLE PROMISSORY NOTE CONVERTIBLE PROMISSORY NOTE $ Atlanta, Georgia Dated as of , 2022 FOR VALUE RECEIVED, the undersigned, GALECTIN THERAPEUTICS, INC., a Nevada corporation (the ?Company?), hereby unconditionally promises to pay to the order of Richard E. Uihlein, an individual resident of the State of Illinois (?Lender?), whose office address is 12575 Uline Drive, Ple |
|
| July 26, 2022 |
Exhibit 10.4 2023 Deferred Stock Unit Agreement under the Galectin Therapeutics Inc. 2019 Omnibus Equity Compensation Plan Pursuant to the terms of the Galectin Therapeutics Inc. 2019 Omnibus Equity Compensation Plan (the ?Plan?), Galectin Therapeutics Inc., a Nevada corporation (the ?Company?) will issue the number of shares of the Company?s common stock equal to the number of Deferred Stock Unit |
|
| July 26, 2022 |
Exhibit 10.1 LINE OF CREDIT LETTER AGREEMENT Dated as of July 25, 2022 GALECTIN THERAPEUTICS, INC. 4960 Peachtree Industrial Blvd., Suite 240 Norcross, Georgia 30071 Gentlemen: Richard E. Uihlein, an individual resident of the State of Illinois (?Uihlein?), hereby confirms that he is holding available to Galectin Therapeutics, Inc., a Nevada corporation (the ?Company?), subject to the restrictions |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 26, 2022 |
Exhibit 10.5 Amendment to Deferred Stock Unit Agreement under the Galectin Therapeutics Inc. 2019 Omnibus Equity Compensation Plan The Deferred Stock Unit Agreement dated August 31, 2020 by and between Galectin Therapeutics Inc. (the ?Company?) and Joel Lewis (?Grantee?) under the Company?s 2019 Omnibus Equity Compensation Plan (the ?Plan?) pursuant to which 80% of the Grantee?s base salary and an |
|
| July 26, 2022 |
Exhibit 99.1 Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it entered into a $60 million unsecured line of credit facility with its chai |
|
| July 26, 2022 |
Exhibit 10.3 First Amendment to Employment Agreement by and Between Galectin Therapeutics Inc. and Joel Lewis The Employment Agreement by and between Galectin Therapeutics Inc. (the ?Company?) and Joel Lewis (?Executive?) dated August 31, 2020 (the ?Employment Agreement?) is hereby amended effective July 25, 2022 as set forth herein (the ?First Amendment?). Capitalized terms not otherwise defined |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 16, 2022 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) ? Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2022. These |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. |
|
| April 14, 2022 |
Exhibit 99.1 Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis NORCROSS, Ga., April 14, 2022 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galect |
|
| April 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 31, 2022 |
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update Exhibit 99.1 Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2022 (GLOBE NEWSWIRE) ? Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2021. These results are included in the Company |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevad |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2022 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 31, 2022 |
Subsidiaries of Galectin Therapeutics Inc. Exhibit 21.1 SUBSIDIARIES OF REGISTRANT The following is a list of the Corporation?s subsidiaries as of December 31, 2021. The Corporation owns, directly or indirectly, 100% of the voting securities of each subsidiary, unless noted otherwise. NAME STATE OR JURISDICTION OF ORGANIZATION Galectin Therapeutics Security Corp. Delaware Galectin Sciences LLC Georgia |
|
| December 21, 2021 |
Exhibit 10.1 NEITHER THIS PROMISSORY NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW AND NEITHER MAY BE SOLD OR OTHERWISE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT AND SUCH APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO, |
|
| December 21, 2021 |
Exhibit 99.1 Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein NORCROSS, Ga., December 21, 2021 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the second $10 million convertible note pursuant to a financing agreement e |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 7, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 3, 2021 |
Exhibit 99.1 Thanks Kevin. And thank you to everyone joining us virtually today. Unfortunately, we are still unable to hold our annual meeting in person due to Covid-19. Hopefully, this will not be the case next year. Regardless, I am grateful that you are listening. Please note that certain statements made today are forward looking in nature. Please see the forward-looking statements disclaimer a |
|
| December 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERAPEUTICS I |
|
| November 15, 2021 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program Leading oncology experts engaged to consult on strategic planning and operational direction in the development of belapectin in cancer immuno |
|
| October 12, 2021 |
TABLE OF CONTENTS United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.????) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commiss |
|
| September 22, 2021 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permi |
|
| September 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 21, 2021 |
Exhibit 10.2 NEITHER THIS PROMISSORY NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW AND NEITHER MAY BE SOLD OR OTHERWISE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT AND SUCH APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO, |
|
| September 21, 2021 |
Exhibit 99.1 Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein NORCROSS, Ga., September 21, 2021 (GLOBE NEWSWIRE) ? Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has entered into a $20 million convertible debt financing agreement with Richard E. Uihlei |
|
| September 21, 2021 |
Exhibit 10.1 LOAN AGREEMENT THIS LOAN AGREEMENT is dated as of September 17, 2021 (the ?Agreement?) by and between GALECTIN THERAPEUTICS, INC., a Nevada corporation (?Borrower?) and RICHARD E. UIHLEIN (the ?Lender?). PRELIMINARY STATEMENTS WHEREAS, on April 16, 2021, Lender loaned Borrower the principal amount of ten million dollars ($10,000,000), as evidenced by that certain convertible promissor |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 13, 2021 |
Corporate Overview September 2021 NASDAQ: GALT www.galectintherapeutics.com Exhibit 99.1 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as ?may,? ?estimate,? ?could,? ?expect? and other |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 16, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 16, 2021 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 16, 2021 |
Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update Considering options for a Combination Cancer Immunotherapy trial based on encouraging results of Phase 1b trial which strengthened the rationale to conduct a larger, randomized controlled Phase 2 study NORCROSS, Ga., August 16, 2021 (GLOBE NEWSWIRE) ? Galectin Therapeutics |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 9, 2021 |
Exhibit 99.1 Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA? in Advanced Metastatic Melanoma and Head and Neck Cancer ? Belapectin and KEYTRUDA? combination immunotherapy in patients with treatment-refractory and progressive diseases shows a cancer control rate of 56% in melanoma and of 40% in head and n |
|
| May 17, 2021 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 17, 2021 |
Exhibit 99.1 D R A F T Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials NORCROSS, Ga., May 17, 2021 (GLOBE NEWSWIRE) ? Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today rep |
|
| April 19, 2021 |
Exhibit 10.1 NEITHER THIS PROMISSORY NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW AND NEITHER MAY BE SOLD OR OTHERWISE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT AND SUCH APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO, |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 31, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN THERA |
|
| March 31, 2021 |
EX-4.20 2 d30125dex420.htm EX-4.20 Exhibit 4.20 DESCRIPTION OF GALECTIN THERAPEUTICS, INC. CAPITAL STOCK As of March 31, 2021, Galectin Therapeutics, Inc. had common stock, $0.001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended, and listed on The NASDAQ Stock Market, LLC under the trading symbol “GALT”. The following description of our common sto |
|
| March 31, 2021 |
Subsidiaries of Galectin Therapeutics Inc. Exhibit 21.1 SUBSIDIARIES OF REGISTRANT The following is a list of the Corporation’s subsidiaries as of December 31, 2020. The Corporation owns, directly or indirectly, 100% of the voting securities of each subsidiary, unless noted otherwise. NAME STATE OR JURISDICTION OF ORGANIZATION Galectin Therapeutics Security Corp. Delaware Galectin Sciences LLC Georgia |
|
| March 31, 2021 |
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update Exhibit 99.1 Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update NORCROSS, Ga. March 31, 2021 ? Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2020. These results are included in the Company?s Annual Re |
|
| March 31, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2021 |
EX-99.1 2 d120371dex991.htm EX-99.1 Corporate Overview March 2021 NASDAQ: GALT www.galectintherapeutics.com Exhibit 99.1 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estima |
|
| March 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2021 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 7, 2020 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 3, 2020 |
EX-99.1 2 d67989dex991.htm EX-99.1 Exhibit 99.1 Thanks Kevin. I want to thank Jack and Beth for putting together our virtual annual meeting, and to all those joining us on the call, I appreciate your participation today. Since we cannot be in Atlanta together, I wanted to personally welcome and wish you a joyous, and most importantly, a healthy holiday season. I look forward to seeing you next yea |
|
| December 3, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 9, 2020 |
EX-99.1 Exhibit 99.1 Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020 Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role – Board Adds Two New Highly Accomplished Professionals NORCROSS, Ga., November 9, 2020 (GLOBE NEWSWIRE) – Galectin Therapeutics Inc. (NASDAQ: GALT), the lea |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No . 001-31791 GALE |
|
| November 9, 2020 |
Form S-8 Registration Statement No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 04-3562325 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 4960 Peachtree Industrial B |
|
| October 19, 2020 |
DEF 14A Table of Contents United States Securities and Exchange Commission Washington, D. |
|
| September 29, 2020 |
EX-99.1 Corporate Overview September 2020 NASDAQ: GALT www.galectintherapeutics.com Exhibit 99.1 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” a |
|
| September 29, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 22, 2020 |
EX-99.1 2 d76730dex991.htm EX-99.1 Exhibit 99.1 Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis NORCROSS, Ga., September 22, 2020 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of thera |
|
| September 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 2, 2020 |
EX-10.2 Exhibit 10.2 DEFERRED STOCK UNIT AGREEMENT UNDER THE GALECTIN THERAPEUTICS INC. 2019 OMNIBUS EQUITY COMPENSATION PLAN August 31, 2020 Pursuant to the terms of the Galectin Therapeutics Inc. 2019 Omnibus Equity Compensation Plan (the “Plan”), Galectin Therapeutics Inc., a Nevada corporation (the “Company”) will issue the number of shares of the Company’s common stock equal to the number of |
|
| September 2, 2020 |
Retirement Agreement, dated August 31, 2020, between Galectin Therapeutics Inc. and Harold Shlevin. EX-10.3 Exhibit 10.3 RETIREMENT AGREEMENT This Retirement Agreement (the “Retirement Agreement”) is entered into as of August 31, 2020, by and between Harold H. Shlevin, Ph.D. ( “Executive”), an individual residing in the State of Florida, and Galectin Therapeutics, Inc. (the “Company”), a Nevada corporation, effective on the date of Executive’s signature below (the “Effective Date”). WHEREAS, Exe |
|
| September 2, 2020 |
EX-99.1 Exhibit 99.1 Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board Board strengthened in scientific expertise with addition of Dr. Elissa Schwartz and in business expertise with Mr. Richard Zordani NORCROSS, Ga., September 2, 2020 (GLOBE NEWSWIRE) – Galec |
|
| September 2, 2020 |
Employment Agreement, dated August 31, 2020, between Galectin Therapeutics Inc. and Joel Lewis EX-10.1 2 d944148dex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made this 31st day of August, 2020 by and between Galectin Therapeutics Inc., a Nevada corporation (the “Company”), and Joel Lewis (“Executive”). W I T N E S S E T H: WHEREAS, Company desires to engage Executive as its Chief Executive Officer, and Executive is willing to accept the |
|
| September 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 2, 2020 |
Consulting Agreement, dated August 31, 2020, between Galectin Therapeutics Inc. and Harold Shlevin. EX-10.4 Exhibit 10.4 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (this “Consulting Agreement”) is made and entered as of the 31st day of August, 2020 (the “Execution Date”), by and between Galectin Therapeutics Inc., a corporation incorporated under the laws of the State of Nevada (the “Company”), and Harold H. Shlevin, Ph.D. (“Shlevin”), an individual residing in the State of Florida. WHEREAS, |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 10, 2020 |
EX-99.1 Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update NASH-RX Trial Continues to Enroll New Patients NORCROSS, Ga., August 10, 2020 (GLOBE NEWSWIRE) – Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business |
|
| August 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-31791 GALECTIN T |
|
| June 30, 2020 |
EX-99.1 2 d89121dex991.htm EX-99.1 Exhibit 99.1 Galectin Therapeutics Announces Commencement of patient enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis Clinical Trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this patient populati |
|
| June 30, 2020 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Co |
|
| June 26, 2020 |
EX-10.1 EXHIBIT 10.1 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. WORK ORDER This WORK ORDER is made the date the last party signs below between: (1) Galectin Therapeutics Inc. whose registered office is at Suite 240, 4960 Peachtree Industrial |
|
| June 26, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Co |
|
| May 19, 2020 |
CORRESP May 19, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-0405 Re: Galectin Therapeutics Inc. Registration Statement on Form S-3 File No. 333-238151 Ladies and Gentlemen: Pursuant to Rules 460 and 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Galectin Therapeutics Inc. (t |
|
| May 18, 2020 |
United States securities and exchange commission logo May 18, 2020 Jack W. Callicutt Chief Financial Officer Galectin Therapeutics Inc. 4960 Peachtree Industrial Blvd. Suite 240 Norcross, GA 30071 Re: Galectin Therapeutics Inc. Registration Statement on Form S-3 Filed May 11, 2020 File No. 333-238151 Dear Mr. Callicutt: This is to advise you that we have not reviewed and will not review your regis |
|
| May 18, 2020 |
United States securities and exchange commission logo May 18, 2020 Jack W. Callicutt Chief Financial Officer Galectin Therapeutics Inc. 4960 Peachtree Industrial Blvd. Suite 240 Norcross, GA 30071 Re: Galectin Therapeutics Inc. Registration Statement on Form S-3 Filed May 11, 2020 File No. 333-238151 Dear Mr. Callicutt: This is to advise you that we have not reviewed and will not review your regis |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 11, 2020 |
Form S-3 Table of Contents Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 2834 04-3562325 (State or other jurisdiction of incorporation or organization) (Primary SIC Number) (I.R.S. Employer Identifi |
|
| May 11, 2020 |
EX-99.1 Exhibit 99.1 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020 Filed a New Form S-3 Shelf Registration Statement Which Replaces the Company’s Existing Shelf Registration Statement, which Expires on June 1, 20 |
|
| May 11, 2020 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2020 |
EX-1.2 2 d830975dex12.htm EX-1.2 Exhibit 1.2 GALECTIN THERAPEUTICS INC. Common Stock (par value $0.001 per share) At The Market Issuance Sales Agreement May 11, 2020 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Galectin Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with H.C. Wainwright & Co., LLC (“Wainwri |
|
| April 30, 2020 |
EX-99.1 Exhibit 99.1 Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis The first patient currently expected to be enrolled in the second quarter of 2020 NORCROSS, Ga., April 30, 2020 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has su |
|
| April 30, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 17, 2020 |
EX-10.2 Exhibit 10.2 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. WORK ORDER This WORK ORDER is made the date the last party signs below between: (1) GALECTIN THERAPEUTICS INC. whose registered office is at Suite 240, 4960 Peachtree Industrial |
|
| March 17, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (C |
|
| March 17, 2020 |
EX-10.1 2 d883597dex101.htm EX-10.1 Exhibit 10.1 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. COVANCE MASTER SERVICES AGREEMENT This Master Services Agreement is effective as of March 12, 2020 (“Effective Date”) by and between (1) Covance Inc. |
|
| March 16, 2020 |
Subsidiaries of Galectin Therapeutics Inc. EX-21.1 Exhibit 21.1 SUBSIDIARIES OF REGISTRANT The following is a list of the Corporation’s subsidiaries as of December 31, 2019. The Corporation owns, directly or indirectly, 100% of the voting securities of each subsidiary, unless noted otherwise. NAME STATE OR JURISDICTION OF ORGANIZATION Galectin Therapeutics Security Corp. Delaware Galectin Sciences LLC Georgia |
|
| March 16, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) (C |
|
| March 16, 2020 |
EX-99.1 Exhibit 99.1 Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis NORCROSS, Ga. March 16, 2020 – Galectin Therapeutics Inc. (NASDAQ: GALT), the leading develope |
|
| March 16, 2020 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 20, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2020 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) |
|
| February 20, 2020 |
EX-10.1 2 d882631dex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made this 19th day of February, 2020, by and between Galectin Therapeutics Inc., a Nevada corporation (the “Company”), and Pol F. Boudes, MD, an individual residing in the State of New Jersey (“Executive”). W I T N E S S E T H: WHEREAS, the Company desires to employ Executive and E |
|
| February 20, 2020 |
EX-99.1 Exhibit 99.1 Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer Appointment of industry veteran reflects growing confidence in clinical development program for NASH Cirrhosis Norcross, GA., February 20, 2020 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in the field of NASH therapeutics, today announced t |
|
| December 6, 2019 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2019 GALECTIN THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 001-31791 04-3562325 (State or Other Jurisdiction of Incorporation) |
